The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A universal influenza A vaccine based on the extracellular domain of the M2 protein
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Evolution and ecology of influenza A viruses
Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M., & Kawaoka, Y. (1992) · Microbiological Reviews · doi:10.1128/mr.56.1.152-179.1992 · Cited by 4,739
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Immunological memory and protective immunity: understanding their relation
Ahmed, R., & Gray, D. (1996) · Science · doi:10.1126/science.272.5258.54 · Cited by 1,775 · cited 1×
“Indeed, B-cell-dependent immunity is usually long-lasting, and can persist for a full human life-span, even in the absence of renewed antigen exposur”
BackgroundSite-directed mutagenesis of virtually any plasmid by eliminating a unique site
Deng, W. P., & Nickoloff, J. A. (1992) · Analytical Biochemistry · doi:10.1016/0003-2697(92)90280-k · Cited by 1,060
The molecular basis of the specific anti-influenza action of amantadine.
Hay, A. J., Wolstenholme, A. J., Skehel, J. J., & Smith, M. H. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04038.x · Cited by 847
Antiviral Activity of 1-Adamantanamine (Amantadine)
Davies, W. L., Grunert, R. R., Haff, R. F., McGahen, J. W., Neumayer, E. M., Paulshock, M., Watts, J. C., Wood, T. R., Hermann, E. C., & Hoffmann, C. E. (1964) · Science · doi:10.1126/science.144.3620.862 · Cited by 838
Adjuvants—a classification and review of their modes of action
Cox, J. C., & Coulter, A. R. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00183-1 · Cited by 682
Plasmid vectors for high-efficiency expression controlled by the promoter of coliphage lambda
Remaut, E., Stanssens, P., & Fiers, W. (1981) · Gene · doi:10.1016/0378-1119(81)90106-2 · Cited by 663
Self-citation(2013) · Wiley eBooks · doi:10.1002/9781118636817 · Cited by 653
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,570
The biology of influenza viruses
Bouvier, N. M., & Palese, P. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.07.039 · Cited by 1,186
Avian Influenza Virus (H5N1): a Threat to Human Health
Peiris, J. S. M., de Jong, M. D., & Guan, Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00037-06 · Cited by 1,007
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L. L. M., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003942 · Cited by 737
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
The 2009 A (H1N1) influenza virus pandemic: A review
Girard, M. P., Tam, J. S., Assossou, O. M., & Kieny, M. P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.05.031 · Cited by 488
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Krammer, F., Pica, N., Hai, R., Margine, I., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.00641-13 · Cited by 423
Jegerlehner, A., Schmitz, N., Storni, T., & Bachmann, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5598 · Cited by 397
Huleatt, J. W., Nakaar, V., Desai, P., Huang, Y., Hewitt, D., Jacobs, A., Tang, J., McDonald, W., Song, L., Evans, R. K., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.10.062 · Cited by 382
The coming of age of virus-like particle vaccines
Jennings, G. T., & Bachmann, M. F. (2008) · bchm · doi:10.1515/bc.2008.064 · Cited by 369
Immune responses to influenza virus infection
Kreijtz, J. H. C. M., Fouchier, R. A. M., & Rimmelzwaan, G. F. (2011) · Virus Research · doi:10.1016/j.virusres.2011.09.022 · Cited by 336
El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N., Verbeek, S., Fiers, W., & Saelens, X. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0902147 · Cited by 335
Self-citationM2e-based universal influenza A vaccine
Fiers, W., De Filette, M., Bakkouri, K. E., Schepens, B., Roose, K., Schotsaert, M., Birkett, A., & Saelens, X. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.007 · Cited by 334
Self-citationNext-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
Virus-like particles: flexible platforms for vaccine development
Chackerian, B. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.3.381 · Cited by 321
Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control.
HILLEMAN, M. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00254-2 · Cited by 319
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach
Talon, J., Salvatore, M., O'Neill, R. E., Nakaya, Y., Zheng, H., Muster, T., García-Sastre, A., & Palese, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070525997 · Cited by 320
Human infection with highly pathogenic H5N1 influenza virus
Gambotto, A., Barratt-Boyes, S. M., de Jong, M. D., Neumann, G., & Kawaoka, Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60627-3 · Cited by 316
Fan, J., Liang, X., Horton, M. S., Perry, H. C., Citron, M. P., Heidecker, G. J., Fu, T.-M., Joyce, J., Przysiecki, C. T., Keller, P. M., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.02.021 · Cited by 315
Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1
Tompkins, S. M., Zhao, Z.-S., Lo, C.-Y., Misplon, J. A., Liu, T., Ye, Z., Hogan, R. J., Wu, Z., Benton, K. A., Tumpey, T. M., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1303.061125 · Cited by 297
Turley, C. B., Rupp, R. E., Johnson, C., Taylor, D. N., Wolfson, J., Tussey, L., Kavita, U., Stanberry, L., & Shaw, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.041 · Cited by 294
Ada, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmra011223 · Cited by 291
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Toward a Universal Influenza Virus Vaccine: Prospects and Challenges
Pica, N., & Palese, P. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-145115 · Cited by 284
HBV Core Particles as a Carrier for B Cell/T Cell Epitopes
Pumpens, P., & Grens, E. (2001) · Intervirology · doi:10.1159/000050037 · Cited by 274
Tumpey, T. M., Renshaw, M., Clements, J. D., & Katz, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.11.5141-5150.2001 · Cited by 253
Metadata
- Authors
- Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M., & Fiers, W.
- Venue
- Nature Medicine
- Published
- 1999-10
- Volume
- 5
- Issue
- 10
- Pages
- 1157-1163
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1546151618
- Cited by
- 752
- References
- 30
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.